Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $201,240.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 4,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $50.31, for a total value of $201,240.00. Following the completion of the sale, the vice president now owns 33,492 shares in the company, valued at approximately $1,684,982.52. This trade represents a 10.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total transaction of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Stock Performance

AKRO stock traded up $1.70 during trading on Friday, reaching $55.64. 800,450 shares of the company's stock were exchanged, compared to its average volume of 989,125. Akero Therapeutics, Inc. has a 1-year low of $20.34 and a 1-year high of $58.40. The firm has a market cap of $4.44 billion, a PE ratio of -14.83 and a beta of -0.12. The company's fifty day moving average price is $41.99 and its 200-day moving average price is $39.35. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Institutional investors have recently modified their holdings of the company. Northwest & Ethical Investments L.P. bought a new stake in Akero Therapeutics in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new stake in shares of Akero Therapeutics in the 4th quarter worth approximately $41,000. PNC Financial Services Group Inc. lifted its stake in Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after purchasing an additional 390 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after buying an additional 1,582 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Akero Therapeutics by 19.0% in the first quarter. Amalgamated Bank now owns 2,570 shares of the company's stock valued at $104,000 after buying an additional 410 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AKRO shares. Bank of America upped their price target on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Citigroup decreased their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.